Login to Your Account

Regulatory NEWS

"Proceed with caution" is the advice the U.S. Patent and Trademark Office (PTO) handed Congress in a report on the availability of confirmatory gene-based testing. Despite the clamoring for access to second-opinion testing that led to the Supreme Court striking down the patentability of the genetic discoveries underlying key diagnostics, the PTO told Congress it found little demand for the confirmatory testing and predicted long-reaching consequences from the court's recent decisions, given the linchpin role genetic testing plays in precision medicine.

LONDON – The EMA's quest for transparency goes on, with the setting down of a framework governing its relationship with the industry.
Not done with the old, but in with the new. That seemed the drumbeat for Vertex Pharmaceuticals Inc., which looked to squeeze out every bit of commercial opportunity for its cystic fibrosis (CF) drug, Kalydeco (ivacaftor), even as it introduced the next generation of CF candidates.
More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: